SpyGlass Pharma, Inc. Common Stock
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Patrick H. Mooney
- Full Time Employees
- 76
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 15326 Alton Parkway Irvine CA United States of America 92618
- IPO Date
- Feb 6, 2026
- CIK
- 0001778922
- Website
- spyglasspharma.com
- Similar Companies
- Business
- SpyGlass Pharma, Inc. is a late-stage biopharmaceutical company focused on transforming chronic eye disease care through durable, long-acting drug delivery solutions. The company specializes in embedding approved ophthalmic medications into proprietary sustained-release platforms to reduce treatment burden for patients and clinicians. Main Products and Services: - BIM-IOL System: an integrated glaucoma therapy delivered during standard cataract surgery, combining intraocular lens implantation with sustained-release glaucoma medication. - BIM-DRS: a broad glaucoma drug-delivery system that extends beyond cataract procedures to enable long-term disease management in a wider patient population. - SpyGlass Drug Delivery Platform: a modular technology designed to incorporate approved drugs into sustained-release formulations for various ophthalmic diseases. - Pipeline programs and feasibility studies: ongoing exploration of additional indications and companion therapies incorporating known drugs with established delivery devices to address chronic eye conditions such as age-related macular degeneration, chronic uveitis, and postoperative care needs. Geographic Operations and Markets: - Headquarters: Aliso Viejo, California, United States. - Primary market: United States, with clinical development activities and potential geographic expansion in other ophthalmology-focused markets. Founding and Corporate Structure: - Founded: 2019 - Public listing: trades on NASDAQ as SGP; information sources indicate ongoing relationships with public market investors and disclosure in line with U.S. regulatory requirements. - Subsidiaries and affiliates: operates as a single corporate entity centered on ophthalmic drug-delivery platforms, with potential collaborations and partnerships as part of a broader strategic program. Latest Major Company Changes: - Strategic partnerships and collaborations to advance sustained-release ophthalmic therapies (including integration into surgical workflows) and broader application of the BIM platforms across glaucoma and other chronic eye diseases. - Advancements in the BIM-IOL and BIM-DRS programs, including potential expansions into additional disease indications and ongoing feasibility studies for long-acting therapies. - Product development pivots toward scaling sustained-delivery technology across therapeutic indications and integrating with established surgical procedures to broaden patient access and outcomes. Industry context and positioning: - Industry: biotechnology and pharmaceutical, with a focus on ophthalmology and drug-delivery technologies. - Business segments: ophthalmic drug delivery platforms, surgical integration products, and pipeline development targeting chronic eye diseases. - Customer types: surgeons, ophthalmology clinics and hospitals, and pharmaceutical partners seeking durable delivery solutions for approved medications.
Company News
SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System
EdgeConneX Enters Australia in Partnership with Stockland, with Hyperscale Data Center Campuses Planned in Sydney and Melbourne
SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability
SpyGlass Pharma, Inc. (SGP) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
SpyGlass Pharma to Participate in Upcoming Investor Conferences
Here Are Friday’s Top Wall Street Analyst Research Calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, Sandisk, T-Mobile US, Wayfair, and More
SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Spyglass Pharma (NASDAQ:SGP) Shares Gap Up – Still a Buy?
Affinity Asset Advisors LLC Buys Shares of 250,000 Spyglass Pharma, Inc. $SGP
SpyGlass Pharma Appoints Shannon Treviño as General Counsel
SpyGlass Pharma Appoints Mike Pinder as Vice President, Marketing
SpyGlass Pharma to Participate in Upcoming Investor Conferences
SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
SpyGlass Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Analyzing Longevity Health (NASDAQ:XAGE) and Spyglass Pharma (NASDAQ:SGP)
Spyglass Pharma, Inc. (NASDAQ:SGP) Receives $45.00 Average PT from Brokerages
SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
Comparing Spyglass Pharma (NASDAQ:SGP) & Nanovibronix (NASDAQ:FEED)
Longevity Health (NASDAQ:XAGE) and Spyglass Pharma (NASDAQ:SGP) Financial Comparison
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System